查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1993111

芽生菌病市场：按产品类型、给药途径、最终用户和分销管道分類的全球市场预测 - 2026-2032 年

Blastomycosis Market by Product Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，芽生菌病市场价值将达到 1.6757 亿美元，到 2026 年将成长至 1.7667 亿美元，到 2032 年将达到 2.1224 亿美元，年复合成长率为 3.43%。

主要市场统计数据
基准年 2025 1.6757亿美元
预计年份：2026年 1.7667亿美元
预测年份 2032 2.1224亿美元
复合年增长率 (%) 3.43%

针对芽生菌病的临床和商业性实施指南，重点在于诊断挑战、治疗途径以及相关人员的策略挑战。

芽生菌病仍是一种未被充分认识的真菌感染疾病，对临床诊疗路径、诊断流程设计和治疗策略产生了深远的影响。虽然疫情爆发相对局限于特定的流行区域，但特异性症状和现有检测方法的局限性给临床医生和医疗系统带来了诊断延迟的巨大挑战。因此，患者的预后取决于早期识别以及可靠诊断工具和有效抗真菌药物治疗方案的可用性。从商业性角度来看，这些临床现实迫切需要诊断技术的创新、分子检测的改进以及标靶治疗。

透过新型诊断技术、改良的治疗方法和供应链调整，重塑芽生菌病治疗的临床路径和市场机会。

芽生菌病的治疗格局正在经历一场变革，这主要得益于技术进步、监管力度加大以及临床实践模式的转变。分子诊断领域的重大创新提高了检测的敏感度和速度，使得早期启动治疗成为可能。同时，血清学检测和影像学检查结果解读框架的改善降低了诊断的不确定性，而诊断不确定性历来是导致治疗延迟和预后不良的原因之一。这些诊断技术的不确定性正在重塑临床路径，并凸显了检查室准备和临床医生教育的重要性。

评估 2025 年关税变化及其对影响芽生菌病相关产品的供应链、采购决策和商业策略的实际影响。

2025年的关税政策变化进一步增加了参与芽生菌病相关诊断和治疗药物生产、进口和分销的利益相关相关人员的复杂性。某些医疗产品关税的提高可能会影响单位经济效益，迫使製造商和经销商重新评估筹资策略、区域生产地点和合约定价模式。对于经常跨境流通的诊断设备和试剂而言，关税导致的成本增加可能会导致医院和检查室的采购週期延长，因为需要重新评估资金分配决策。

可操作的细分讯息，解释产品、最终用户、分销和管理方法的差异，以促进产品的采用、采购和临床应用。

市场区隔揭示了产品类型、最终用户、分销管道和给药途径等关键转折点，这些因素共同决定了市场动态和临床应用。依产品类型划分，市场大致分为诊断与治疗两大类。诊断产品再细分为影像学、分子检测和血清学检测，而治疗产品则分为Azole和Polyenes，Azole再细分为Fluconazole和Itraconazole。这些产品层面的区分会影响临床工作流程、投资重点以及相关人员认可的上市证据类型。

区域差异和策略反映了流行病模式、医疗保健系统和法规环境，从而影响实施准备和需求。

芽生菌病的区域性流行趋势反映了各主要地区流行病学、医疗基础设施和法律规范的差异。在美洲，特定地区的流行状态引起了临床关注，催生了对快速诊断方法和有效抗真菌药物的需求。同时，完善的医院网路和实验室系统正为采用先进的分子检测技术铺路。在欧洲、中东和非洲，监测能力和诊断可近性的差异导致需求多样化。一些市场优先考虑价格合理的血清学检测和能力建设，而拥有先进三级医疗中心的市场则专注于尖端分子诊断平台和特效疗法。

企业策略和伙伴关係模式揭示了诊断和治疗公司如何透过证据产生、供应链韧性和临床参与来脱颖而出。

在企业层面，一个多元化的生态系统正在形成，旨在满足芽生菌病的临床需求，该生态系统涵盖诊断试剂开发商、製药企业和专业经销商。一些主要相关人员优先投资于分子诊断平台，透过提高检测灵敏度和优化工作流程来缩短诊断时间；而其他公司则专注于提升血清学检测性能和增强影像辅助工具。在治疗领域，拥有成熟抗真菌药物产品组合的製造商正致力于优化製剂配方、提升安全性，并透过医学教育和管理专案支持符合指南的用药。

为领导者提供切实可行的综合建议，以加快诊断方法的采用，优化治疗方法的使用，并确保整个市场供应链的韧性。

致力于巩固自身在芽生菌病治疗领域地位的产业领导者应优先考虑一系列兼顾临床价值和商业性可行性的综合策略。首先，应投资进行严谨的诊断检验研究，以证明药物在具有代表性的患者群体中具有真实世界的敏感性和特异性，并将这些证据与临床医生教育倡议相结合，从而减少诊断延迟。其次，应优化治疗方案的实施，考虑以患者为中心的製剂研发进展和清晰的处方指南，以解决安全性和依从性问题，同时与药物管理计画合作，以维持治疗方案的长期疗效。

采用透明、多方面的研究途径，整合主要临床发现、权威文献和严格检验，以确保提供实用见解。

本研究采用多面向方法，结合一手和二手证据，建构芽生菌病临床和商业性趋势的全面图景。一手资料将透过访谈感染疾病专家、检查室管理人员、医院药剂师和分销专员收集，以获取关于诊断性能、治疗决策、采购实践和区域准入障碍的第一手观点。这些定性研究结果将与同行评审的临床文献、监管指导文件和公开的治疗指南进行交叉比对，以确保临床准确性。

该策略结论强调，需要将诊断创新、治疗优化和强有力的商业化联繫起来，以改善患者的治疗效果。

总之，芽生菌病治疗领域的不断演变为能够协调诊断创新、治疗优化和稳健商业化策略的相关人员提供了明确的机会。提高诊断速度和准确性仍然是减轻临床负担和改善患者预后的最直接途径。同时，优先考虑安全性、给药柔软性和实际应用支援的治疗方案将有助于增强所有医疗机构的治疗连续性。区域差异凸显了製定符合当地流行病模式、医疗基础设施和采购惯例的区域性策略的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：芽生菌病市场：依产品类型划分

  • 诊断药物
    • 诊断影像
    • 分子检测
    • 血清学检测
  • 治疗药物
    • Azole药物
      • Fluconazole
      • Itraconazole
    • Polyenes

第九章：芽生菌病市场：依给药途径划分

  • 静脉
  • 口服
    • 胶囊
    • 口服液体药物

第十章：芽生菌病市场：依最终用户划分

  • 门诊部
  • 诊断检查室
  • 医院

第十一章：芽生菌病市场：依通路划分

  • 直接竞标
  • 销售代理
  • 线上零售

第十二章：芽生菌病市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：芽生菌病市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：芽生菌病市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国芽生菌病市场

第十六章：中国芽生菌病市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Amphastar Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Celltrion Healthcare Co., Ltd.
  • CSL Limited
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • IMMY, Inc.
  • Johnson & Johnson
  • Luminex Corporation
  • Merck & Co., Inc.
  • Meridian Bioscience, Inc.
  • MycoMed Technologies
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.
  • Viatris Inc.
Product Code: MRR-1A1A064C0289

The Blastomycosis Market was valued at USD 167.57 million in 2025 and is projected to grow to USD 176.67 million in 2026, with a CAGR of 3.43%, reaching USD 212.24 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 167.57 million
Estimated Year [2026] USD 176.67 million
Forecast Year [2032] USD 212.24 million
CAGR (%) 3.43%

A focused clinical and commercial introduction to blastomycosis emphasizing diagnostic hurdles, therapeutic pathways, and strategic imperatives for stakeholders

Blastomycosis remains an underrecognized fungal infection with outsized implications for clinical pathways, diagnostic workflow design, and therapeutic strategy. Although incidence is relatively localized in endemic regions, clinicians and health systems face significant diagnostic delays owing to nonspecific presentations and limitations in current testing modalities. Consequently, patient outcomes hinge on timely recognition and the availability of reliable diagnostic tools paired with effective antifungal regimens. From a commercial perspective, these clinical realities translate into distinct demand drivers for diagnostics innovation, improved molecular assays, and targeted therapeutics.

In addition, evolving awareness among frontline clinicians and public health authorities is beginning to reshape detection efforts, which in turn affects procurement cycles and formulary decisions. Diagnostic laboratories and hospitals must balance speed, sensitivity, and cost when selecting tests, while ambulatory care settings increasingly require accessible point-of-care solutions. Therapeutic selection is influenced by route of administration, patient comorbidities, and tolerability, with oral azoles and intravenous polyenes continuing to play established roles. Taken together, these dynamics create an environment where strategic investment in diagnostic accuracy and therapeutic optimization offers the greatest potential for clinical and commercial impact.

Emerging diagnostic innovations, therapeutic refinements, and supply chain adaptations reshaping clinical pathways and market opportunities in blastomycosis care

The landscape for blastomycosis is undergoing transformative shifts driven by technological advances, regulatory attention, and changing clinical practice patterns. Key innovations in molecular diagnostics are increasing the sensitivity and speed of detection, enabling earlier initiation of therapy. Simultaneously, refinements in serological assays and imaging interpretation frameworks are helping to reduce diagnostic uncertainty, which historically contributed to treatment delays and poorer outcomes. These diagnostic improvements are reshaping clinical pathways and elevating the importance of laboratory readiness and clinician education.

On the therapeutic front, stewardship considerations and evolving evidence on azole efficacy and safety are prompting more nuanced prescribing practices. The balance between oral and intravenous administration is influenced by patient acuity and care setting, while formulation improvements aim to enhance adherence and tolerability. Moreover, supply chain resilience and distribution channel optimization are becoming strategic priorities as stakeholders seek to ensure uninterrupted access to critical diagnostics and antifungals. Together, these trends are converging to create new opportunities for diagnostic manufacturers, pharmaceutical developers, and health systems to collaborate on integrated care models that reduce time-to-diagnosis and improve patient outcomes.

Assessment of 2025 tariff shifts and their practical implications for supply chains, procurement decisions, and commercial strategies impacting blastomycosis products

Tariff policy changes in 2025 have introduced an additional layer of complexity for stakeholders involved in the manufacture, importation, and distribution of diagnostics and therapeutics relevant to blastomycosis. Increased duties on certain medical goods can influence unit economics, prompting manufacturers and distributors to reassess sourcing strategies, regional production footprints, and contractual pricing models. For diagnostic equipment and reagents that cross borders frequently, tariff-induced cost inflation can translate into delayed procurement cycles for hospitals and laboratories as capital allocation decisions are revisited.

At the same time, therapeutics that depend on international raw materials or finished-good imports face potential margin pressure that may affect availability or lead to preferential stocking of domestically produced alternatives where feasible. In response, many firms are intensifying efforts to localize supply chains, diversify supplier bases, and negotiate longer-term purchasing agreements to stabilize costs. Payers and purchasing groups are likely to play a more prominent role in mediating access and cost-containment, and manufacturers will need to align commercial strategies with evolving reimbursement conversations and procurement tender practices to preserve market access amid tariff volatility.

Actionable segmentation intelligence describing product, end-user, distribution, and administration distinctions that drive adoption, procurement, and clinical use

Segmentation reveals critical inflection points across product types, end users, distribution channels, and administration routes that collectively define market dynamics and clinical adoption. Based on Product Type, the landscape spans Diagnostics and Therapeutics, with Diagnostics further differentiated by Imaging, Molecular Test, and Serological Test, and Therapeutics further divided into Azoles and Polyenes, with Azoles also split between Fluconazole and Itraconazole. These product-level distinctions influence clinical workflows, investment priorities, and the types of evidence stakeholders will accept for adoption.

Based on End User, demand patterns vary across Ambulatory Care Settings, Diagnostic Laboratories, and Hospitals, each with distinct purchasing cycles, volume requirements, and clinical priorities. Based on Distribution Channel, procurement and logistics differ when sourced via Direct Tender, Distributor, or Online Retail, affecting time-to-market and inventory management. Based on Route Of Administration, choices between Intravenous and Oral therapies shape inpatient versus outpatient treatment pathways, and the Oral category itself is further delineated into Capsules and Oral Solution, which have implications for adherence, dosing flexibility, and patient preference. Understanding these intersecting segmentation dimensions enables more precise targeting of clinical evidence generation, commercialization tactics, and supply chain design.

Geographic differentiation and regional strategies reflecting endemic patterns, healthcare capabilities, and regulatory environments that shape readiness and demand

Regional dynamics for blastomycosis reflect divergent epidemiology, healthcare infrastructure, and regulatory frameworks across major geographies. In the Americas, endemicity in certain regions drives concentrated clinical awareness, shaping demand for rapid diagnostics and effective antifungal options, while established hospital networks and laboratory systems create pathways for adoption of advanced molecular assays. In Europe, Middle East & Africa, variable surveillance capacity and differential access to diagnostics lead to heterogeneous needs; some markets prioritize affordable serological tests and capacity building, whereas others with advanced tertiary centers focus on cutting-edge molecular platforms and specialist therapeutics.

In the Asia-Pacific region, increasing investment in laboratory infrastructure, rising clinician familiarity with fungal infections, and expanding private-sector distribution networks are fueling opportunities for both diagnostics and therapeutics. Cross-regionally, regulatory harmonization, reimbursement mechanisms, and supply chain resilience emerge as common themes that influence how products are introduced and scaled. Consequently, tailored regional strategies that account for endemicity, healthcare delivery models, and payer environments are essential for successful market entry and sustained uptake.

Corporate strategies and partnership models revealing how diagnostics and therapeutics players differentiate through evidence generation, supply resilience, and clinical engagement

Company-level dynamics show a diverse ecosystem of diagnostic developers, pharmaceutical manufacturers, and specialized distributors engaged in addressing blastomycosis clinical needs. Leading stakeholders that prioritize investment in molecular diagnostic platforms are accelerating time-to-diagnosis through assay sensitivity and workflow integration, while others focus on improving serology performance and imaging interpretation support tools. On the therapeutics side, manufacturers with established antifungal portfolios concentrate on optimizing formulations, improving safety profiles, and supporting guideline-compliant use through medical education and stewardship programs.

Strategic partnerships between diagnostic companies and clinical networks are becoming more common, enabling validation studies and smoother adoption pathways. Similarly, collaborations between pharmaceutical firms and hospital systems can support real-world evidence generation and formulary inclusion. Competitive differentiation increasingly rests on the ability to demonstrate clinical utility, cost-effectiveness, and supply reliability. As a result, companies investing in clinician outreach, robust post-market surveillance, and flexible distribution arrangements are better positioned to capture clinical trust and long-term institutional relationships.

Pragmatic and integrated recommendations for leaders to accelerate diagnostic adoption, optimize therapeutic use, and secure resilient supply chains across markets

Industry leaders seeking to strengthen their position in blastomycosis care should prioritize a set of integrated actions that align clinical value with commercial viability. First, invest in robust diagnostic validation studies that demonstrate real-world sensitivity and specificity across representative patient cohorts, and pair that evidence with clinician-facing educational initiatives to reduce diagnostic delay. Second, optimize therapeutic offerings by considering patient-centric formulation advances and clear prescribing guidance that addresses safety and adherence concerns, while coordinating with stewardship programs to preserve therapeutic longevity.

Third, fortify supply chain resilience through supplier diversification, localized manufacturing where feasible, and flexible distribution agreements that mitigate tariff and logistic risks. Fourth, tailor market entry and scaling strategies to regional healthcare systems by aligning regulatory strategies, reimbursement dossiers, and local clinical champions. Fifth, engage in collaborative partnerships across diagnostics, therapeutics, and hospital networks to build integrated care pathways that shorten time-to-diagnosis and improve outcomes. Implementing these steps with clear KPIs and cross-functional governance will translate strategic intent into measurable impact.

Transparent multi-method research approach integrating primary clinical insights, authoritative literature synthesis, and rigorous validation to ensure actionable findings

This research adopts a multi-method approach combining primary and secondary evidence streams to construct a comprehensive view of blastomycosis clinical and commercial dynamics. Primary inputs include interviews with infectious disease clinicians, laboratory directors, hospital pharmacists, and distribution specialists to capture firsthand perspectives on diagnostic performance, therapeutic decision-making, procurement practices, and regional access barriers. These qualitative insights are triangulated with peer-reviewed clinical literature, regulatory guidance documents, and publicly available treatment guidelines to ensure clinical accuracy.

Analytical methods encompass segmentation analysis to delineate meaningful clinical and commercial cohorts, scenario planning to assess supply chain and tariff impacts, and company profiling to map strategic positioning and partnership activity. Data validation steps include cross-checking interview findings against published studies and regulatory sources, as well as reconciling discrepancies through follow-up conversations. The methodology emphasizes transparency, reproducibility, and relevance to decision-makers, and it is designed to support both strategic planning and operational implementation.

Strategic conclusion emphasizing the imperative for coordinated diagnostic innovation, therapeutic optimization, and resilient commercialization to improve patient outcomes

In conclusion, the evolving landscape of blastomycosis care presents clear opportunities for stakeholders who can align diagnostic innovation, therapeutic optimization, and resilient commercialization strategies. Improving diagnostic speed and accuracy remains the most direct lever to reduce clinical burden and improve patient outcomes, while therapeutic choices that prioritize safety, administration flexibility, and real-world support will enhance care continuity across settings. Regional differences underscore the need for bespoke approaches that reflect endemic patterns, healthcare infrastructure, and procurement norms.

Furthermore, recent tariff dynamics and supply chain pressures highlight the strategic importance of sourcing flexibility and distribution agility. Companies that invest in evidence generation, clinician engagement, and operational robustness will be best positioned to translate scientific advances into clinical adoption and institutional trust. Ultimately, coordinated action across manufacturers, health systems, and policymakers is required to close gaps in detection and treatment, and to ensure that patients receive timely, effective care regardless of geography.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blastomycosis Market, by Product Type

  • 8.1. Diagnostics
    • 8.1.1. Imaging
    • 8.1.2. Molecular Test
    • 8.1.3. Serological Test
  • 8.2. Therapeutics
    • 8.2.1. Azoles
      • 8.2.1.1. Fluconazole
      • 8.2.1.2. Itraconazole
    • 8.2.2. Polyenes

9. Blastomycosis Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Oral Solution

10. Blastomycosis Market, by End User

  • 10.1. Ambulatory Care Settings
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals

11. Blastomycosis Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Distributor
  • 11.3. Online Retail

12. Blastomycosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blastomycosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blastomycosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Blastomycosis Market

16. China Blastomycosis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Amphastar Pharmaceuticals, Inc.
  • 17.7. Astellas Pharma Inc.
  • 17.8. Bayer AG
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. BioMerieux SA
  • 17.11. Celltrion Healthcare Co., Ltd.
  • 17.12. CSL Limited
  • 17.13. Fresenius Kabi AG
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline plc
  • 17.16. Hikma Pharmaceuticals plc
  • 17.17. IMMY, Inc.
  • 17.18. Johnson & Johnson
  • 17.19. Luminex Corporation
  • 17.20. Merck & Co., Inc.
  • 17.21. Meridian Bioscience, Inc.
  • 17.22. MycoMed Technologies
  • 17.23. Novartis AG
  • 17.24. Pfizer Inc.
  • 17.25. Sandoz International GmbH
  • 17.26. Sanofi S.A.
  • 17.27. Sun Pharmaceutical Industries Ltd.
  • 17.28. Teva Pharmaceutical Industries Ltd.
  • 17.29. Thermo Fisher Scientific, Inc.
  • 17.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLASTOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLASTOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 191. NATO BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)